Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in Early Breast Cancer (TRIO030)
NCT03004534Phase 1Completed
- Sponsor
- Translational Research In Oncology
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of darolutamide in breast cancer, sponsored by Translational Research In Oncology. Primary endpoint: Molecular Alterations in Breast Cancer Tissue. Started Sep 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03004534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004534.